Evidence map›Paper›PMID 23902488›Full record

ArticleThe New England journal of medicine2013

Participant-level data and the new frontier in trial transparency.

Deborah A Zarin

Registry-linked trialAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00104299 (Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00104299 phase2 / phase3completednot on this map

Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2005 to 2010Enrolled197ConditionsVasculitis, Wegener's Granulomatosis, Microscopic PolyangiitisArmsRituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Learning disease relationships from clinical drug trials.Journal of the American Medical Informatics Association : JAMIA · 2017
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Deborah A Zarin

Funding

ClinicalTrial Registration and Results ReportingZIALM008926 · NLM · NATIONAL LIBRARY OF MEDICINE · PI ZARIN, DEBORAH · 2009 to 2014
$4.3M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Access to InformationClinical Trials as TopicDrug IndustryInformation DisseminationAntibodies, Monoclonal, Murine-DerivedAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAzathioprineCyclophosphamideHumansImmunologic FactorsRituximabAntibodies, Monoclonal, Murine-DerivedAzathioprineCyclophosphamideImmunologic FactorsRituximab

Identifiers

PMID23902488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.